Literature DB >> 18202344

Pseudomonas aeruginosa in chronic obstructive pulmonary disease.

Timothy F Murphy1, Aimee L Brauer, Karen Eschberger, Phyllis Lobbins, Lori Grove, Xueya Cai, Sanjay Sethi.   

Abstract

RATIONALE: Pseudomonas aeruginosa is isolated from adults with chronic obstructive pulmonary disease (COPD) in cross-sectional studies. However, patterns of carriage and the role of P. aeruginosa in COPD are unknown.
OBJECTIVES: To elucidate carriage patterns, phenotypes of strains, clinical manifestations, and the antibody response to P. aeruginosa in COPD.
METHODS: A prospective study of adults with COPD was conducted. Isolates of P. aeruginosa were subjected to genotypic and phenotypic analysis. Sputum samples were studied for P. aeruginosa DNA, and immune responses were assayed.
MEASUREMENTS AND MAIN RESULTS: We analyzed longitudinal clinical data, sputum cultures, pulsed-field gel electrophoresis of bacterial DNA, polymerase chain reaction of sputum, and immunoblot assays of serum. Fifty-seven episodes of acquisition of strains of P. aeruginosa were observed in 39 of 126 patients over 10 years. Acquisition of a new strain was associated with exacerbation. Thirty-one episodes of carriage were followed by clearance of the strain; 16 were of short (<1 mo) duration. Thirteen strains demonstrated persistence, and 13 strains were of indeterminate duration. Six strains were mucoid and were more likely to persist than nonmucoid strains (P = 0.005). Antibody responses developed in 53.8% of persistent carriage and in only 9.7% of short-term carriage episodes (P = 0.003). Antibiotics did not account for clearance.
CONCLUSIONS: Two distinct patterns of carriage by P. aeruginosa were observed: (1) short-term colonization followed by clearance and (2) long-term persistence. Mucoid strains showed persistence. Acquisition of P. aeruginosa is associated with the occurrence of an exacerbation. Serum antibody responses do not mediate clearance of P. aeruginosa.

Entities:  

Mesh:

Year:  2008        PMID: 18202344     DOI: 10.1164/rccm.200709-1413OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  102 in total

1.  Linoleic acid supplement in cystic fibrosis: friend or foe?

Authors:  Neeraj Vij
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-08-13       Impact factor: 5.464

2.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

3.  Airway Mucus Hyperconcentration in Non-Cystic Fibrosis Bronchiectasis.

Authors:  Kathryn A Ramsey; Alice C H Chen; Giorgia Radicioni; Rohan Lourie; Megan Martin; Amy Broomfield; Yong H Sheng; Sumaira Z Hasnain; Graham Radford-Smith; Lisa A Simms; Lucy Burr; David J Thornton; Simon D Bowler; Stephanie Livengood; Agathe Ceppe; Michael R Knowles; Peadar G Noone; Scott H Donaldson; David B Hill; Camille Ehre; Brian Button; Neil E Alexis; Mehmet Kesimer; Richard C Boucher; Michael A McGuckin
Journal:  Am J Respir Crit Care Med       Date:  2020-03-15       Impact factor: 21.405

4.  Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model.

Authors:  Christopher J Harvey; Rajesh K Thimmulappa; Sanjay Sethi; Xiaoni Kong; Lonny Yarmus; Robert H Brown; David Feller-Kopman; Robert Wise; Shyam Biswal
Journal:  Sci Transl Med       Date:  2011-04-13       Impact factor: 17.956

Review 5.  Mechanisms and Targeted Therapies for Pseudomonas aeruginosa Lung Infection.

Authors:  Colleen S Curran; Thomas Bolig; Parizad Torabi-Parizi
Journal:  Am J Respir Crit Care Med       Date:  2018-03-15       Impact factor: 21.405

6.  A Comparison between Two Pathophysiologically Different yet Microbiologically Similar Lung Diseases: Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.

Authors:  Daniel E Fenker; Cameron T McDaniel; Warunya Panmanee; Ralph J Panos; Eric J Sorscher; Carleen Sabusap; John P Clancy; Daniel J Hassett
Journal:  Int J Respir Pulm Med       Date:  2018-11-29

7.  Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease.

Authors:  Yvonne J Huang; Sanjay Sethi; Timothy Murphy; Snehal Nariya; Homer A Boushey; Susan V Lynch
Journal:  J Clin Microbiol       Date:  2014-05-21       Impact factor: 5.948

Review 8.  Chronic obstructive pulmonary disease (COPD): evaluation from clinical, immunological and bacterial pathogenesis perspectives.

Authors:  Daniel J Hassett; Michael T Borchers; Ralph J Panos
Journal:  J Microbiol       Date:  2014-03-01       Impact factor: 3.422

9.  Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.

Authors:  Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; V N Maturu; Sahajal Dhooria; K T Prasad; Inderpaul S Sehgal; Lakshmikant B Yenge; Aditya Jindal; Navneet Singh; A G Ghoshal; G C Khilnani; J K Samaria; S N Gaur; D Behera
Journal:  Lung India       Date:  2013-07

10.  Cigarette Smoke Exposure Promotes Virulence of Pseudomonas aeruginosa and Induces Resistance to Neutrophil Killing.

Authors:  Jason Chien; John H Hwang; Sedtavut Nilaad; Jorge A Masso-Silva; Sae Jeong Ahn; Elisa K McEachern; Alexander Moshensky; Min-Kwang Byun; Laura E Crotty Alexander
Journal:  Infect Immun       Date:  2020-10-19       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.